ClinicalTrials.gg
RecruitingNCT06562192Updated Jul 29, 2026

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

A Phase 1 interventional study of [68Ga]Ga-NNS309 and [177Lu]Lu-NNS309 in Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer and HR+/HER2- Ductal and Lobular Breast Cancer, sponsored by Novartis Pharmaceuticals. Recruiting at 29 sites in 10 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
162
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis — 8 open to participants now, 15 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Novartis.

Planned enrollment
29th of 92
162 · median 91
Started
2024
the only one that year
Phase 1
34 of 101
6 open now
Primary completion
2031-01
later than 12 of 14 live
Registered
95th of 101
by date

Among the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, this one is the 29th largest by planned enrollment of the 92 interventional ones that give a count, is the only one that started in 2024, is one of 34 in phase 1, reaches primary completion later than 12 of the 14 other live ones, and was the 95th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Carcinoma, Non-Small-Cell Lung by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety, dosimetry and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Read the detailed description

The study will be done in two parts. The first part is called "escalation" and the second part is called "expansion". In both parts of the study, patients will initially be imaged with a [68Ga]Ga-NNS309 positron emission tomography (PET)/ computed tomography (CT) or PET/magnetic resonance imaging (MRI) scan and will be evaluated for eligibility for [177Lu]Lu-NNS309 treatment. In the escalation part, different doses of [177Lu]Lu-NNS309 will then be tested to identify recommended dose(s) (RD(s)) for further evaluation. The expansion part of the study will examine the safety and preliminary efficacy of [177Lu]Lu-NNS309 at the RD(s) determined during the escalation part. The end of study will occur when all patients per disease group in the expansion part have completed the follow-up for disease progression or discontinued from the study for any reason, and all patients have completed treatment and the 36-month long-term follow-up period.

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma
  • Non-small Cell Lung Cancer
  • HR+/HER2- Ductal and Lobular Breast Cancer
  • Triple Negative Breast Cancer
  • Colorectal Cancer

Keywords

  • pancreatic ductal adenocarcinoma
  • non-small cell lung cancer
  • breast cancer
  • colorectal cancer
  • radioligand therapy (RLT)
  • [177Lu]Lu-NNS309
  • [68Ga]Ga-NNS309
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old
  • Patients with one of the following indications:
  • Locally advanced unresectable or PDAC with disease progression following, or intolerance to cytotoxic chemotherapy, unless patient was ineligible to receive such therapy
  • Locally advanced unresectable or metastatic NSCLC without any actionable genomic alterations with disease progression following, or intolerance to chemotherapy and immunotherapy, unless patient was ineligible to receive such therapy, or locally advanced unresectable or metastatic NSCLC with an actionable genomic alteration with disease progression following, or intolerance to targeted therapy, unless patient was ineligible to receive such therapy
  • Locally advanced unresectable or metastatic HR+/- ductal or lobular BC with disease progression following, or intolerance to, at least 2 , unless patient was ineligible to receive such therapy
  • Locally advanced unresectable or metastatic TNBC with disease progression following, or intolerance to, at least 2 lines of therapy, unless patient was ineligible to receive such therapy
  • Locally advanced or metastatic unresectable CRC with disease progression following, or intolerance to cytotoxic chemotherapy, unless patient was ineligible to receive such therapy. Patients with known microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) status must also have had disease progression following, or intolerance to therapy, unless patient was ineligible to receive such therapy
  • Patients must have lesions showing 68Ga-NNS309 uptake

Exclusion criteria

Exclusion Criteria:

  • (ANC) \< 1.5 x 10\^9/L, \< 9 g/dL, or count \< 100 x 10\^9/L
  • corrected by Fridericia's formula (QTcF) ≥ 470 msec
  • Calculated estimated \< 60 mL/min/1.73m2
  • Unmanageable urinary tract obstruction or urinary incontinence
  • Radiation therapy within 4 weeks prior to the first dose of [177Lu]Lu-NNS309

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
162 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Patients will receive \[68Ga\]Ga-NNS309, and if eligible, \[177Lu\]Lu-NNS309

    Drug: [68Ga]Ga-NNS309 · Drug: [177Lu]Lu-NNS309

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients with dose limiting toxicities of [177Lu]Lu-NNS309

    A dose limiting toxicity (DLT) is defined as any adverse event or abnormal laboratory value of CTCAE (version 5.0) Grade 3 or higher that occurs within the DLT evaluation period and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with a few exceptions defined in the study protocol. Other clinically significant toxicities may be considered to be DLTs, even if not Grade 3 or higher.

    Time frame: From start of study treatment until 6 weeks or 4 weeks after, depending on dosing schedule

  2. Incidence and severity of adverse events and serious adverse events of [177Lu]Lu-NNS309

    The distribution of adverse events will be done via the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) and through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From start of study treatment until completion of the 36 month follow up, assessed up to approximately 42 months

  3. Dose modifications for [177Lu]Lu-NNS309

    Dose modifications (dose interruptions and reductions) for \[177Lu\]Lu-NNS309 will be assessed and summarized using descriptive statistics. The number of patients with dose modification will be summarized by treatment groups.

    Time frame: From start of study treatment until last dose of study treatment, assessed up to approximately 24 weeks

  4. Dose intensity for [177Lu]Lu-NNS309

    Dose intensity for \[177Lu\]Lu-NNS309 will be assessed and summarized using descriptive statistics. Dose intensity is computed as the ratio of actual cumulative dose received and actual duration of exposure.

    Time frame: From start of study treatment until last dose of study treatment, assessed up to approximately 24 weeks

Secondary outcomes

  1. Overall response rate (ORR)

    ORR is defined as the proportion of patients with a BOR of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 guidelines.

    Time frame: Up to approximately 42 months

  2. Duration of Response (DOR)

    DOR is the time between the first documented response (CR or PR) and the date of progression according to RECIST v1.1 guidelines, or death due to any cause.

    Time frame: Up to approximately 42 months

  3. Disease control rate (DCR)

    DCR is defined as the proportion of patients with a BOR of CR, PR or stable disease according to RECIST v1.1 guidelines.

    Time frame: Up to approximately 42 months

  4. Progression free survival (PFS)

    PFS is defined as the time from the date of start of treatment to the date of the first documented progression according to RECIST v1.1 guidelines or death due to any cause.

    Time frame: Up to approximately 42 months

  5. Area Under the Curve (AUC) of [177Lu]Lu-NNS309

    The \[177Lu\]Lu-NNS309 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. AUC will be determined by non-compartmental methods.

    Time frame: Samples collected pre infusion to 336 hours post end of infusion in Cycle 1. In a subset of patients, sampling is repeated in Cycle 2 and subsequent cycles. Cycle duration is 4 or 6 weeks.

  6. Total body clearance of [177Lu]Lu-NNS309

    The \[177Lu\]Lu-NNS309 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Total body clearance will be determined by non-compartmental methods.

    Time frame: Samples collected pre infusion to 336 hours post end of infusion in Cycle 1. In a subset of patients, sampling is repeated in Cycle 2 and subsequent cycles. Cycle duration is 4 or 6 weeks.

  7. Observed maximum blood concentration (Cmax) of [177Lu]Lu-NNS309

    The \[177Lu\]Lu-NNS309 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Cmax will be determined by non-compartmental methods.

    Time frame: Samples collected pre infusion to 336 hours post end of infusion in Cycle 1. In a subset of patients, sampling is repeated in Cycle 2 and subsequent cycles. Cycle duration is 4 or 6 weeks.

  8. Observed maximum radioactivity concentration (Rmax) of [177Lu]Lu-NNS309

    The \[177Lu\]Lu-NNS309 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Rmax will be determined by non-compartmental methods.

    Time frame: Samples collected pre infusion to 336 hours post end of infusion in Cycle 1. In a subset of patients, sampling is repeated in Cycle 2 and subsequent cycles. Cycle duration is 4 or 6 weeks.

  9. Volume of distribution (Vz) of [177Lu]Lu-NNS309 during the terminal phase

    The \[177Lu\]Lu-NNS309 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Vz will be determined by non-compartmental methods.

    Time frame: Samples collected pre infusion to 336 hours post end of infusion in Cycle 1. In a subset of patients, sampling is repeated in Cycle 2 and subsequent cycles. Cycle duration is 4 or 6 weeks.

  10. Terminal elimination half-life (T1/2) of [177Lu]Lu-NNS309

    The \[177Lu\]Lu-NNS309 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. T1/2 will be determined by non-compartmental methods.

    Time frame: Samples collected pre infusion to 336 hours post end of infusion in Cycle 1. In a subset of patients, sampling is repeated in Cycle 2 and subsequent cycles. Cycle duration is 4 or 6 weeks.

  11. Urinary excretion of radioactivity expressed as a percentage of injected dose (%ID)

    Urine elimination data for \[177Lu\]Lu-NNS309 will be assessed based on decay-corrected urine radioactivity concentration data. Urine elimination data will be expressed as percentage of injected dose (%ID).

    Time frame: Cycle 1: Pre-infusion, beginning of infusion to first SPECT/CT image acquisition, first SPECT/CT image acquisition to 6 hr post end of infusion (EOI), 6-24hr post EOI, 24-48hr post EOI, 48-72hr post EOI. The duration of a cycle is 4 weeks or 6 weeks.

  12. Renal clearance of [177Lu]Lu-NNS309

    Urine samples will be collected over specified time intervals and analyzed for radioactivity. Renal clearance of 177Lu-NNS309 will be summarized using descriptive statistics.

    Time frame: Cycle 1: Pre-infusion, beginning of infusion to first SPECT/CT image acquisition, first SPECT/CT image acquisition to 6 hr post end of infusion (EOI), 6-24hr post EOI, 24-48hr post EOI, 48-72hr post EOI. The duration of a cycle is 4 weeks or 6 weeks.

  13. Absorbed dose of [177Lu]Lu-NNS309

    Time activity curves (TACs) for the various organs and tumor lesions will be produced as fraction of injected activity per gram of tissue (%ID/g) as a function of time.

    Time frame: Samples collected 5 hours to 336 hours post end of infusion in Cycle 1. In a subset of patients, sampling is repeated in Cycle 2 and subsequent cycles. Cycle duration is 4 or 6 weeks.

  14. Absorbed radiation dose of [68Ga]Ga-NNS309 in tumor lesions (dose expansion only)

    Time activity curves (TACs) for the tumor lesions will be produced as fraction of injected activity per gram of tissue (%ID/g) as a function of time.

    Time frame: Samples collected 30 minutes to 3 hours post end of injection.

  15. Area Under the Curve (AUC) of [68Ga]Ga-NNS309

    The \[68Ga\]Ga-NNS309 pharmacokinetic analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. AUC will be determined by non-compartmental methods.

    Time frame: Samples collected 5 minutes to 245 minutes post end of injection.

  16. Incidence and severity of adverse events and serious adverse events of [68Ga]Ga-NNS309

    The distribution of adverse events will be done via the analysis of frequencies for TEAEs and TESAEs and through the monitoring of relevant clinical and laboratory safety parameters.

    Time frame: From Imaging visit until 3 days after 68Ga-NNS309 administration, assessed up to approximately 3 days.

  17. Visual and quantitative assessment of [68Ga]Ga-NNS309 uptake in normal tissues and tumor lesions over time

    After \[68Ga\]Ga-NNS309 administration, \[68Ga\]Ga-NNS309 PET/CT or PET/MRI will be performed. Standardized uptake values (SUVs) of \[68Ga\]Ga-NNS309 in normal tissues and tumor lesions over time will be summarized.

    Time frame: From 0 up to approximately 3 hrs after [68Ga]Ga-NNS309 dosing

07

Study locations

29 of 29 sites recruiting
  • Uni of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
    Recruiting
    • Quenteeria Mooney · Contactqmooney@uabmc.edu
    • Jonathan McConathy · Principal investigator
  • University of California LA
    Los Angeles, California 90095, United States
    Recruiting
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
    Recruiting
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
    Recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • BAMF Health
    Grand Rapids, Michigan 49503, United States
    Recruiting
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
    • Lucas Hamann · Contacthamann.lucas@mayo.edu · +1 507 538 2155
    • Andrea Wahner Hendrickson · Principal investigator
  • Uni Of TX MD Anderson Cancer Cntr
    Houston, Texas 77030, United States
    Recruiting
  • University Of Washington
    Seattle, Washington 98109, United States
    Recruiting
  • Novartis Investigative Site
    Brussels, 1000, Belgium
    Recruiting
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H2X 1R9, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H3T 1E2, Canada
    Recruiting
  • Novartis Investigative Site
    Bron, 69677, France
    Recruiting
  • Novartis Investigative Site
    Villejuif, 94800, France
    Recruiting
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
    Recruiting
  • Novartis Investigative Site
    Essen, 45147, Germany
    Recruiting
  • Novartis Investigative Site
    München, 80377, Germany
    Recruiting
  • Novartis Investigative Site
    Rostock, 18057, Germany
    Recruiting
  • Novartis Investigative Site
    Tel Aviv, 6423906, Israel
    Recruiting
  • Novartis Investigative Site
    Milan, MI 20133, Italy
    Recruiting
  • Novartis Investigative Site
    Reggio Emilia, RE 42123, Italy
    Recruiting
  • Novartis Investigative Site
    Nijmegen, Gelderland 6500HB, Netherlands
    Recruiting
  • Novartis Investigative Site
    Utrecht, 3584 CX, Netherlands
    Recruiting
  • Novartis Investigative Site
    Barcelona, 08036, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28009, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28040, Spain
    Recruiting
  • Novartis Investigative Site
    Geneva, 1211, Switzerland
    Recruiting
  • Novartis Investigative Site
    Lausanne, 1011, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Jan 2031, 75 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 75 months is above that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2024
First posted
Aug 20, 2024
StartActual
Oct 15, 2024
Primary completionEst.
Jan 15, 2031
CompletionEst.
Jan 16, 2031
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06562192
Responsible party
Sponsor
First posted
Aug 20, 2024
Start date
Oct 15, 2024
Primary completion
Jan 15, 2031 (estimated)
Completion
Jan 16, 2031 (estimated)
Last update
Jul 29, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+41613241111

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion